Skip to main content
SpringerLink
Log in
Book cover

Handbook of Multiple Myeloma pp 41–63Cite as

Treatment of elderly patients with myeloma

  • Chapter
  • First Online:

  • 1234 Accesses

Abstract

In Europe and North America, the majority of patients diagnosed with cancer are over 65 years of age. This particularly applies to myeloma, a clonal late B-cell disorder, with a median age at diagnosis of 69 years of age. Besides differences in terms of tumor biology, cancer decisionmaking in the elderly is often complicated by the presence of comorbidities and psychosocial factors. We provide a comprehensive review of the epidemiology, biological and clinical features of this disease in elderly patients as well as the diagnostic and treatment strategies that may be implemented in this population.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. National Cancer Institute. SEER Stat fact sheets: myeloma. http://seer.cancer.gov/statfacts/html/mulmy.html. Accessed May 22, 2015.

  2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.

    Google Scholar 

  3. Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009;27:2758–2765.

    Google Scholar 

  4. Office for National Statistics (ONS). Cancer incidence and mortality in the United Kingdom, 2008–10. www.ons.gov.uk/ons/rel/cancer-unit/cancer-incidence-and-mortality/2008-2010/rft-cancer-incidence-and-mortality-in-the-uk–2008-2010.xls. Accessed May 22, 2015.

  5. European commission. The 2012 ageing report. Economic and budgetary projections for the 27 EU Member States (2010–2060). http://ec.europa.eu/economy_finance/publications/european_economy/2012/pdf/ee-2012-2_en.pdf. Accessed May 22, 2015.

  6. Avet-Loiseau H, Hulin C, Campion L, et al. Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myelome experience. J Clin Oncol. 2013;31:2806–2809.

    Google Scholar 

  7. Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415–421.

    Google Scholar 

  8. Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. J Am Geriatr Soc. 1968;16:622–626.

    Google Scholar 

  9. Palumbo A, Bringhen S, Ludwig H, Dimopoulos MA, Blade J, Mateos MV, et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood. 2011 Oct 27;118:4519–29.

    Google Scholar 

  10. Palumbo A, Rajkumar SV, San Miguel JF, et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol. 2014;32:587–600.

    Google Scholar 

  11. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–e548.

    Google Scholar 

  12. Mallappallil M, Friedman EA, Delano BG, McFarlane SI, Salifu MO. Chronic kidney disease in the elderly: evaluation and management. Clin Pract (Lond). 2014;11:525–535.

    Google Scholar 

  13. Patel KV . Epidemiology of anemia in older adults. Semin Hematol. 2008;45:210–217.

    Google Scholar 

  14. Goodnough LT, Schrier SL. Evaluation and management of anemia in the elderly. Am J Hematol. 2014;89:88–96.

    Google Scholar 

  15. Guralnik JM, Eisenstaedt RS, Ferrucci L, Klein HG, Woodman RC . Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood. 2004;104:2263–2268.

    Google Scholar 

  16. Price EA, Mehra R, Holmes TH, Schrier SL. Anemia in older persons: etiology and evaluation. Blood Cells Mol Dis. 2011;46:159–165.

    Google Scholar 

  17. Pennypacker LC, Allen RH, Kelly JP, et al. High prevalence of cobalamin deficiency in elderly outpatients. J Am Geriatr Soc. 1992;40:1197–1204.

    Google Scholar 

  18. Rawstron AC, Child JA, de Tute RM, et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol. 2013;31:2540–2547.

    Google Scholar 

  19. Davies FE, Forsyth PD, Rawstron AC, et al. The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma. Br J Haematol. 2001;112:814–819.

    Google Scholar 

  20. Larocca A, Cavallo, F, Magarotto V, Palumbo A. Reduced dose-intensity subcutaneous bortezomib plus prednisone (VP) or plus cyclophosfamide (VCP) or plus melphalan (VMP) for newly diagnosed multiple myeloma patients older than 75 years of age. Blood. 2013;122:539.

    Google Scholar 

  21. Barlogie B, Mitchell A, van Rhee F, Epstein J, Morgan GJ, Crowley J. Curing myeloma at last: defining criteria and providing the evidence. Blood. 2014;124:3043–3051.

    Google Scholar 

  22. Niesvizky R, Richardson PG, Rajkumar SV, et al. The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. Br J Haematol. 2008;143:46–53.

    Google Scholar 

  23. Gay F, Larocca A, Wijermans P, et al. Complete response correlates with long-term progressionfree and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood. 2011;117:3025–3031.

    Google Scholar 

  24. Larocca A, Child JA, Cook G, et al. The impact of response on bone-directed therapy in patients with multiple myeloma. Blood. 2013;122:2974–2977.

    Google Scholar 

  25. Facon T, Mary JY, Pegourie B, et al. Dexamethasone-based regimens versus melphalanprednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood. 2006;107:1292–1298.

    Google Scholar 

  26. Alexanian R, Bergsagel DE, Migliore PJ, Vaughn WK, Howe CD . Melphalan therapy for plasma cell myeloma. Blood. 1968;31:1–10.

    Google Scholar 

  27. Cavo M, Benni M, Ronconi S, et al. Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study. Haematologica. 2002;87:934–942.

    Google Scholar 

  28. Schey SA, Cavenagh J, Johnson R, Child JA, Oakervee H, Jones RW. An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment. Leuk Res. 2003;27:909–914.

    Google Scholar 

  29. Ludwig H, Hajek R, Tothova E, et al. Thalidomide-dexamethasone compared with melphalanprednisolone in elderly patients with multiple myeloma. Blood. 2009;113:3435–3442.

    Google Scholar 

  30. Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet. 2007;370:1209–1218.

    Google Scholar 

  31. Fayers PM, Palumbo A, Hulin C, et al. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood. 2011;118:1239–1247.

    Google Scholar 

  32. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:1046–1060.

    Google Scholar 

  33. Wijermans P, Schaafsma M, Termorshuizen F, et al. Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. J Clin Oncol. 2010;28:3160–3166.

    Google Scholar 

  34. Hulin C, Facon T, Rodon P, et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol. 2009;27:3664–3670.

    Google Scholar 

  35. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet. 2006;367:825–831.

    Google Scholar 

  36. Palumbo A, Bringhen S, Liberati AM, et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood. 2008;112:3107–3114.

    Google Scholar 

  37. Waage A, Gimsing P, Fayers P, et al. Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood. 2010;116:1405–1412.

    Google Scholar 

  38. Beksac M, Haznedar R, Firatli-Tuglular T, et al. Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. Eur J Haematol. 2011;86:16–22.

    Google Scholar 

  39. Morgan GJ, Davies FE, Gregory WM, et al. Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood. 2011;118:1231–1238.

    Google Scholar 

  40. Morgan GJ, Davies FE, Gregory WM, et al. Long-term follow-up of MRC Myeloma IX trial: survival outcomes with bisphosphonate and thalidomide treatment. Clin Cancer Res. 2013;19:6030–6038.

    Google Scholar 

  41. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487–2498.

    Google Scholar 

  42. Richardson PG, Sonneveld P, Schuster MW, et al. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. Br J Haematol. 2007;137:429–435.

    Google Scholar 

  43. Hideshima T, Richardson PG, Anderson KC . Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Mol Cancer Ther. 2011;10:2034–2042.

    Google Scholar 

  44. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359:906–917.

    Google Scholar 

  45. San Miguel JF, Schlag R, Khuageva NK, et al. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. J Clin Oncol. 2013;31:448–455.

    Google Scholar 

  46. San-Miguel JF, Richardson PG, Sonneveld P, et al. Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia. 2008;22:842–849.

    Google Scholar 

  47. Mateos M-V, Oriol A, Martinez-Lopez J, et al. Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial. Blood. 2012;120:2581–2588.

    Google Scholar 

  48. Palumbo A, Bringhen S, Larocca A, et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomibmelphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. J Clin Oncol. 2014;32:634–640.

    Google Scholar 

  49. Palumbo A, Bringhen S, Rossi D, et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomibmelphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol. 2010;28:5101–5109.

    Google Scholar 

  50. Mateos MV, Oriol A, Martinez-Lopez J, et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol. 2010;11:934–941.

    Google Scholar 

  51. Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12:431–440.

    Google Scholar 

  52. Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 2007;110:3557–3560.

    Google Scholar 

  53. Celgene. FDA expands infication for REVLIMIDR (lenalidomide) in combination with dexamethasone to include patients newly diagnosed with dexamethasone to include patients newly diagnosed with multiple myeloma. http://ir.celgene.com/releasedetail. cfm?ReleaseID=896912. Accessed May 22, 2015.

  54. Benboubker L, Dimopoulos MA, Dispenzieri A, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014;371:906–917.

    Google Scholar 

  55. Falco P, Cavallo F, Larocca A, et al. Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients. Leukemia. 2013;27:695–701.

    Google Scholar 

  56. Stewart AK, Jacobus SJ, Fonseca R, et al. E1A06: A phase III trial comparing melphalan, prednisone, and thalidomide (MPT) versus melphalan, prednisone, and lenalidomide (MPR) in newly diagnosed multiple myeloma (MM). J Clin Oncol. 2014;32:5s (suppl; abstr 8511).

    Google Scholar 

  57. Pawlyn C. Lenalidomide combined with cyclophosphamide and dexamethasone is effective and well tolerated induction treatment for newly diagnosed myeloma patients of all ages. Paper presented at: 55th AS H Annual Meeting and Exposition; December 7–10, 2013; New Orleans, LA.

    Google Scholar 

  58. Pönisch W, Mitrou PS, Merkle K, et al. Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone–a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol. 2006;132:205–212.

    Google Scholar 

  59. Rodon P, Hulin C, Pegourie B, et al. Phase 2 study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial. Haematologica. 2014; [Epub ahead of print]; doi:10.3324/haematol.2014.110890.

  60. Siegel DS, Desikan KR, Mehta J, et al. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood. 1999;93:51–54.

    Google Scholar 

  61. Gertz MA, Dingli D. How we manage autologous stem cell transplantation for patients with multiple myeloma. Blood. 2014;124:882–890.

    Google Scholar 

  62. Badros A, Barlogie B, Siegel E, et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol. 2001;114:600–607.

    Google Scholar 

  63. Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet. 2007;370:1209–1218.

    Google Scholar 

  64. Ozaki S, Shimizu K. Autologous stem cell transplantation in elderly patients with multiple myeloma: past, present, and future. BioMed Res Int. 2014;2014:1-7.

    Google Scholar 

  65. Boyd KD, Ross FM, Chiecchio L, et al. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia. 2012;26:349–355.

    Google Scholar 

  66. Lee AYY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146–153.

    Google Scholar 

  67. Larocca A, Cavallo F, Bringhen S, et al. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood. 2012;119: 933–939; quiz 1093.

    Google Scholar 

  68. Boyle EM, Fouquet G, Manier S, et al. Immunomodulator drug-based therapy in myeloma and the occurrence of thrombosis. Expert Rev Hematol. 2012;5:617–626; quiz 627.

    Google Scholar 

  69. Kastritis E, Terpos E, Dimopoulos MA. Current treatments for renal failure due to multiple myeloma. Expert Opin Pharmacother. 2013;14:1477–1495.

    Google Scholar 

  70. Hirschberg R. Renal complications from bisphosphonate treatment. Curr Opin Support Palliat Care. 2012;6:342–347.

    Google Scholar 

  71. Jackson GH, Morgan GJ, Davies FE, et al. Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results. Br J Haematol. 2014;166:109–117.

    Google Scholar 

  72. Harousseau JL, Attal M. The role of stem cell transplantation in multiple myeloma. Blood Rev. 2002;16:245–253.

    Google Scholar 

  73. Fahdi IE, Gaddam V, Saucedo JF, et al. Bradycardia during therapy for multiple myeloma with thalidomide. Am J Cardiol. 2004;93:1052–1055.

    Google Scholar 

  74. Yamaguchi T. Syncope and sinus bradycardia from combined use of thalidomide and beta-blocker. Pharmacoepidemiol Drug Saf. 2008;17:1033–1035.

    Google Scholar 

  75. Chen N, Weiss D, Reyes J, et al. No clinically significant drug interactions between lenalidomide and P‑glycoprotein substrates and inhibitors: results from controlled phase I studies in healthy volunteers. Cancer Chemother Pharmacol. 2014;73:1031–1039.

    Google Scholar 

  76. Azad N, Lemay G. Management of chronic heart failure in the older population. J Geriatr Cardiol. 2014;11:329–337.

    Google Scholar 

  77. Wu W, Merriman K, Nabaah A, et al. The association of diabetes and anti-diabetic medications with clinical outcomes in multiple myeloma. Br J Cancer. 2014;111:628–636.

    Google Scholar 

  78. Sonneveld P, Verelst SG, Lewis P, et al. Review of health-related quality of life data in multiple myeloma patients treated with novel agents. Leukemia. 2013;27:1959–1969.

    Google Scholar 

  79. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609–2617.

    Google Scholar 

  80. Ludwig H, Sonneveld P, Davies F, et al. European perspective on multiple myeloma treatment strategies in 2014. Oncologist. 2014;19:829–844.

    Google Scholar 

  81. Terpos E, Morgan G, Dimopoulos MA, et al. International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. J Clin Oncol. 2013;31:2347–2357.

    Google Scholar 

  82. Lahtinen R, Laakso M, Palva I, Virkkunen P, Elomaa I. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group. Lancet. 1992;340:1049–1052.

    Google Scholar 

  83. Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol. 1998;16:593–602.

    Google Scholar 

  84. Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer. 2004;100:2613–2221.

    Google Scholar 

  85. Morgan GJ, Child JA, Gregory WM, et al. Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial. Lancet Oncol. 2011;12:743–752.

    Google Scholar 

  86. Rades D, Veninga T, Stalpers LJA, et al. Outcome after radiotherapy alone for metastatic spinal cord compression in patients with oligometastases. J Clin Oncol. 2007;25:50–56.

    Google Scholar 

  87. Berenson J, Pflugmacher R, Jarzem P, et al. Balloon kyphoplasty versus non-surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: a multicentre, randomised controlled trial. Lancet Oncol. 2011;12:225–235.

    Google Scholar 

  88. Groll AH, Castagnola E, Cesaro S, et al. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. Lancet Oncol. 2014;15:e327–e340.

    Google Scholar 

  89. Vickrey E, Allen S, Mehta J, Singhal S. Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy. Cancer. 2009;115:229–232.

    Google Scholar 

  90. Chanan-Khan A, Sonneveld P, Schuster MW, et al. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol. 2008;26:4784–4790.

    Google Scholar 

  91. Nuorti JP, Whitney CG, Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010;59:1–18.

    Google Scholar 

  92. Dupire S, Wemeau M, Debarri H, et al. Prognostic value of PINI index in patients with multiple myeloma. Eur J Haematol. 2012;88:306–313.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Hôpital Claude Huriez, Lille, France

    Eileen M. Boyle, Charline Legrand, Hélène Demarquette, Stéphanie Guidez, Charles Herbaux, Xavier Leleu & Thierry Facon

Authors
  1. Eileen M. Boyle
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Charline Legrand
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hélène Demarquette
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stéphanie Guidez
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Charles Herbaux
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xavier Leleu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Thierry Facon
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Clinical Hematology and Cellular Therapy Department, Université Pierre and Marie Curie, Hospital Saint-Antoine, Paris, Paris, France

    Mohamad Mohty

  2. Department of Hematology, Centre René Gauducheau, Nantes Atlantique (Saint-Herblain), Nantes, France

    Jean-Luc Harousseau

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Boyle, E.M. et al. (2015). Treatment of elderly patients with myeloma. In: Mohty, M., Harousseau, JL. (eds) Handbook of Multiple Myeloma. Adis, Cham. https://doi.org/10.1007/978-3-319-18218-6_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-18218-6_4

  • Published:

  • Publisher Name: Adis, Cham

  • Print ISBN: 978-3-319-18217-9

  • Online ISBN: 978-3-319-18218-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation